Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology · Myelodysplastic Neoplasms

Understanding Your MDS Diagnosis: First Steps

At a Glance

Myelodysplastic Syndromes (MDS), now formally called Myelodysplastic Neoplasms, are blood cancers where the bone marrow fails to produce healthy blood cells. Because MDS is highly variable, your care team will use specific genetic tests to determine your risk and tailor a personal treatment plan.

Hearing that you have Myelodysplastic Syndromes (MDS) can feel like your world has suddenly shifted. It is completely normal to feel overwhelmed, anxious, or even panicked [1]. You may be dealing with “illness uncertainty”—a common experience where the complexity of the disease makes it hard to see the path forward [2].

This page is designed to help you catch your breath. By understanding the modern definition of MDS and a few stabilizing facts, you can move from a state of panic to a state of informed preparation.

What is MDS?

In 2022, international medical experts updated the formal name of this condition to Myelodysplastic Neoplasms [3]. While doctors still use the abbreviation MDS, the change from “syndrome” to “neoplasm” was made to clarify that this is a clonal blood cancer [3][4].

At its core, MDS is a bone marrow disorder characterized by ineffective hematopoiesis [5].

  • Hematopoiesis is the process your body uses to make new blood cells.
  • Ineffective means the process is broken. Your bone marrow creates blood cells that are defective, fail to mature properly, and die prematurely (apoptosis) before they can enter your bloodstream [6][7].

This leads to cytopenias, which is the medical term for low blood counts [8]. The most common result is anemia (low red blood cells), which often causes the intense fatigue many patients feel [9][10].

Three Stabilizing Facts

When you are first diagnosed, it is easy to focus on the worst-case scenarios. These three facts can help ground your perspective:

  1. MDS is highly variable: No two cases are exactly alike. MDS ranges from “lower-risk” types that may stay stable for many years with minimal treatment to “higher-risk” types that require more intensive care [11][12]. Your experience will be specific to your unique biological markers.
  2. It is a disease of aging: You are not alone in this. MDS primarily affects older adults; the median age at diagnosis is between 70 and 76 years old [13][14]. While the general incidence is about 4 per 100,000 people, it rises to 25 per 100,000 in those over age 65 [13][15].
  3. New tools provide better clarity: Doctors now use advanced genetic testing and updated scoring systems, like the IPSS-M (International Prognostic Scoring System-Molecular), to understand your specific risk [2][16]. This allows for a more personalized treatment plan than was possible even a few years ago [17].

Navigating the “Watch and Wait” Phase

If you have lower-risk MDS, your doctor might recommend a “watch and wait” (or active surveillance) approach [18]. While it can feel counterintuitive to not “fight” a cancer immediately, this strategy is often used to protect your quality of life while monitoring the disease closely [19].

If you feel anxious during this time, it is important to share those feelings with your care team, as supportive care (treatments aimed at relieving symptoms and stress, such as receiving occasional blood transfusions or growth factor shots for energy) can be started at any time [19].

Common questions in this guide

What is the difference between Myelodysplastic Syndromes and Neoplasms?
In 2022, medical experts updated the name from syndrome to neoplasm to clarify that MDS is a type of clonal blood cancer. Doctors still use the abbreviation MDS, but the new name better reflects how the disease originates in the bone marrow.
What does ineffective hematopoiesis mean in MDS?
Hematopoiesis is how your body makes new blood cells. In MDS, this process is ineffective because the bone marrow creates defective cells that die before they can mature and enter the bloodstream, resulting in low blood counts.
What is an IPSS-M score?
The International Prognostic Scoring System-Molecular (IPSS-M) is an advanced tool doctors use to understand your specific risk level with MDS. It incorporates genetic testing and molecular data to help your care team create a personalized treatment plan based on your unique biology.
Why would my doctor recommend a watch and wait approach for MDS?
For lower-risk types of MDS, doctors often use active surveillance, or watch and wait, to protect your quality of life. During this time, they monitor your condition closely and may offer supportive care to manage symptoms without immediately starting intensive treatments.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the WHO 2022 guidelines, what is my specific subtype of Myelodysplastic Neoplasm?
  2. 2.What is my risk score according to the IPSS-M (Molecular) or IPSS-R (Revised) systems?
  3. 3.Am I currently in a 'lower-risk' or 'higher-risk' category, and what does that mean for my immediate treatment plan?
  4. 4.What was the 'blast percentage' in my bone marrow, and why is this number important for my diagnosis?
  5. 5.Do I have any specific genetic mutations, such as SF3B1 or TP53, that change my prognosis or treatment options?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Clonal evolution in inherited marrow failure syndromes predicts disease progression.

    Schratz KE

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):125-134 doi:10.1182/hematology.2023000469.

    PMID: 38066914
  2. 2

    Experiences with Higher-Risk Myelodysplastic Syndromes and Improving Patient-Centered Treatment Decision-Making: A Qualitative Study of Patients, Caregivers, and Providers.

    Maravic MC, Land N, Prood N, et al.

    Cancer management and research 2025; (17()):1215-1232 doi:10.2147/CMAR.S482570.

    PMID: 40584227
  3. 3

    Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

    Kubasch AS, Giagounidis A, Metzgeroth G, et al.

    Leukemia 2022; (36(10)):2519-2527 doi:10.1038/s41375-022-01669-z.

    PMID: 36071100
  4. 4

    Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.

    Falini B, Martelli MP

    American journal of hematology 2023; (98(3)):481-492 doi:10.1002/ajh.26812.

    PMID: 36606297
  5. 5

    Introduction to the Review Series on Myelodysplasia.

    Mittelman M

    Haematologica 2025; (110(2)):281-282 doi:10.3324/haematol.2023.284948.

    PMID: 39895333
  6. 6

    Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.

    Huang H, Xu C, Gao J, et al.

    Blood cancer journal 2020; (10(8)):83 doi:10.1038/s41408-020-00349-4.

    PMID: 32801296
  7. 7

    Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.

    Maggioni G, Della Porta MG

    Current opinion in hematology 2023; (30(2)):30-37 doi:10.1097/MOH.0000000000000752.

    PMID: 36728601
  8. 8

    Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

    Stahl M, Bewersdorf JP, Xie Z, et al.

    Blood reviews 2023; (62()):101128 doi:10.1016/j.blre.2023.101128.

    PMID: 37704469
  9. 9

    Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.

    Cazzola M, Malcovati L

    Hematology. American Society of Hematology. Education Program 2015; (2015()):19-25 doi:10.1182/asheducation-2015.1.19.

    PMID: 26637696
  10. 10

    Management of older adults with myelodysplastic syndromes (MDS).

    Luskin MR, Abel GA

    Journal of geriatric oncology 2018; (9(4)):302-307 doi:10.1016/j.jgo.2017.12.002.

    PMID: 29290596
  11. 11

    Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.

    Badar T, Madanat YF, Zeidan AM

    Future oncology (London, England) 2023; (19(27)):1877-1889 doi:10.2217/fon-2023-0454.

    PMID: 37750305
  12. 12

    Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.

    Komrokji RS

    Clinical lymphoma, myeloma & leukemia 2016; (16 Suppl()):S39-43.

    PMID: 27521322
  13. 13

    Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.

    Sekeres MA, Taylor J

    JAMA 2022; (328(9)):872-880 doi:10.1001/jama.2022.14578.

    PMID: 36066514
  14. 14

    A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.

    Bewersdorf JP, Mina A, Stahl M, Zeidan AM

    Nature reviews. Clinical oncology 2026; (23(7)):481-500 doi:10.1038/s41571-026-01141-2.

    PMID: 41981151
  15. 15

    Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.

    Zeidan AM, Shallis RM, Wang R, et al.

    Blood reviews 2019; (34()):1-15 doi:10.1016/j.blre.2018.09.001.

    PMID: 30314642
  16. 16

    Risk stratifying MDS in the time of precision medicine.

    Cazzola M

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):375-381 doi:10.1182/hematology.2022000349.

    PMID: 36485160
  17. 17

    Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.

    Zhang Y, Wu J, Qin T, et al.

    Leukemia 2022; (36(12)):2875-2882 doi:10.1038/s41375-022-01718-7.

    PMID: 36224330
  18. 18

    Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

    Stauder R, Yu G, Koinig KA, et al.

    Leukemia 2018; (32(6)):1380-1392 doi:10.1038/s41375-018-0089-x.

    PMID: 29572506
  19. 19

    Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.

    Niscola P, Gianfelici V, Giovannini M, et al.

    Annals of hematology 2026; (105(5)).

    PMID: 42081107

This page provides educational information about an initial MDS diagnosis. It does not replace professional medical advice, and you should always discuss your specific IPSS-M score and treatment plan with your hematologist or oncologist.

Get notified when new evidence is published on Myelodysplastic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.